www.neurology.org/doi/10.1212/...
www.neurology.org/doi/10.1212/...
Tempest Therapeutics exclusively licensed Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, including lead BCMA/GPRC5D candidate TPST-4903, following initial Phase 1 results.
Market-relevant event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Tempest Therapeutics exclusively licensed Senlang’s CD7-targeted lentiviral in vivo CAR-T platform, including lead BCMA/GPRC5D candidate TPST-4903, following initial Phase 1 results.
Market-relevant event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
https://www.stocktitan.net/news/TPST/tempest-therapeutics-exercises-option-to-license-senlang-s-cd7-u1x80eiplocj.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/TPST/tempest-therapeutics-exercises-option-to-license-senlang-s-cd7-u1x80eiplocj.html?utm_source=stocktitan-bluesky&utm_medium=social
clinical.med-iq.com/series/advan...
clinical.med-iq.com/series/advan...
Modernaが、mRNA-2808の初期臨床データをASH年次総会で口頭発表する。再発・難治性多発性骨髄腫で12例中4例に奏効が見られた。Moderna、mRNA-2808の初期臨床データをASH年次総会で口頭発表へ──再発・難治性多発性骨髄腫で12例中4例に奏効
stellanews.life/technology/1...
Modernaが、mRNA-2808の初期臨床データをASH年次総会で口頭発表する。再発・難治性多発性骨髄腫で12例中4例に奏効が見られた。Moderna、mRNA-2808の初期臨床データをASH年次総会で口頭発表へ──再発・難治性多発性骨髄腫で12例中4例に奏効
stellanews.life/technology/1...
https://www.stocktitan.net/news/CGEM/cullinan-therapeutics-announces-presentations-for-cln-049-a-flt3-t-2d2pc4nssm6m.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CGEM/cullinan-therapeutics-announces-presentations-for-cln-049-a-flt3-t-2d2pc4nssm6m.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.mattheneus.com/editorial/has-talvey-talquetamab-monotherapy-post-bcma-benefit-indirect-evidence-2026-09-09
#HTA #MAIC #EvidenceSynthesis
https://www.mattheneus.com/editorial/has-talvey-talquetamab-monotherapy-post-bcma-benefit-indirect-evidence-2026-09-09
#HTA #MAIC #EvidenceSynthesis
Read more: sohoinsider.com/multiple-mye...
Read more: sohoinsider.com/multiple-mye...
buff.ly/x0KPnwv
buff.ly/x0KPnwv
https://openbionews.com/analysis/daily-bio-news-summary-2026-10-28/
https://openbionews.com/analysis/daily-bio-news-summary-2026-10-28/
A phase 1 study reports that dual CD19/BCMA CAR-T therapy induced profound but transient B-cell depletion, ⬇️HLA sensitization, & enabled kidney transplantation in 2 highly sensitized patients
🔗DOI: 10.1056/NEJMoa2513428
A phase 1 study reports that dual CD19/BCMA CAR-T therapy induced profound but transient B-cell depletion, ⬇️HLA sensitization, & enabled kidney transplantation in 2 highly sensitized patients
🔗DOI: 10.1056/NEJMoa2513428
To learn more about this year's sponsors, visit: museum.bc.ca/2026-bcma-co...
To learn more about this year's sponsors, visit: museum.bc.ca/2026-bcma-co...
▪️ 38 patients traités
▪️ Taux de réponse global : 100 %
▪️ Rémission complète : 79 %
▪️ Survie sans progression à 24 mois : 57 %
www.aerzteblatt.de/news/multipl...
▪️ 38 patients traités
▪️ Taux de réponse global : 100 %
▪️ Rémission complète : 79 %
▪️ Survie sans progression à 24 mois : 57 %
www.aerzteblatt.de/news/multipl...
To learn more about this year's conference sponsors, visit our website: museum.bc.ca/2026-bcma-co...
Thank you for your support!
To learn more about this year's conference sponsors, visit our website: museum.bc.ca/2026-bcma-co...
Thank you for your support!